Notizia - Recent Pharma, Healthcare and Biotech Happenings

EMA to review Cidara Therapeutics’ Rezafungin; EU Approves Gilead Sciences’ Sunlenca; FDA Approves Axsome’s Auvelity; EU Marketing Authorisation to Oncopeptides’s Pepaxti; Merck Signs $ 3.5 B Deal with Orna; FDA to review AstraZeneca and Merck’s Lynparza; FDA Approval to Bluebird’s Zynteglo; FDA Decision Date for GSK’s Momelotinib

EU Regulator Starts its Review of Cidara Therapeutics’ Candidiasis Therapy Rezafungin The EU regulator has begun its review of Cidara Therapeutics’ once-weekly antifungal rezafungin, with a decision expected next year as a new option for serious, invasive candida infections. The application is based on the ReSTORE trial, which demonstrated that rezafungin, an echinocandin, was as effective as daily dosing with the decades-old drug caspofungin in severe candidemia and invasive candidiasis. Rezafungin, if approved, would be the first new front-line therapy for severe candida infections in well over a decade, providing a much-needed new option for patients who do not ...

Explore More...

Pfizer’s Somatrogon; SCONE device; ATG-010; SanBio in Neurology

Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results

recent-pharma-happenings-for-senseonics-alkermes-hologic

Improving cancer immunotherapy; Senseonics’ Eversense delayed; FDA acknowledges Alkermes’ Resubmission; 3D breast ultrasound improves diagnosis

Myovant Pfizer Deal_Generic for Severe Hypoglycemia_Teleflex

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

recent-pharma-biotech-healthcare-news-and-updates-for-nih-roche-regeneron-gsk

NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche’s bispecific matches Eylea; Research Updates in Leukemia, solid tumors

Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

Atsena raises $55M; Neuron23’s strategy for CNS disorders; and more

Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders

Historic win for Pfizer's COVID-19 Vaccine; Alexion Buyout; and more

FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel

recent-pharma-biotech-news-updates-for-astrazeneca-uniqure-csl

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

KaliVir, Astellas deal; AbCellera IPO; Bayer's CAR-T collabs; NASH therapy

KaliVir, Astellas licensing deal; AbCellera’s IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH

recent-pharma-biotech-news-and-updates-for-zimmer-bayer-ovid-merck-janssen-roche

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

pharma-biotech-news-and-updates-for-dna-link-base10-takeda-advaxis

BASE10 Collaboration; Advaxis Public offerings; Takeda’s CABOMETYX Japan approval; TheraPharm Acquisition

Pharma happenings for Urovant's vibegron Genmab and Polyphor

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant’s vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic

recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent

Novartis’ COVID-19 deal; Shattered hopes for Remdesivir; Lilly’s R&D pact with Precision; Innovent’s Humira Biosimilar

recent-pharma-happenings-for-pfizer-sanofi-elevation-oncology

Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M

Albireo's PFIC Therapy; Lupin’s Trichomoniasis Drug; Moderna's COVID vaccine; NASH Cocktail Therapy

Albireo Pharma’s PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna’s Weapon Against COVID; Gilead & Novo Nordisk’s Cocktail Therapy for NASH

recent-pharma-news-and-updates-for-egenesis-duke-decibel-genscript

FDA authorizes first diagnostic test for Covid-19 antibodies; EGenesis’s collaboration with Duke; Pancreatic Cancer research updates; Decibel scores $ 82 M

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pfizer/ OPKO Health’s Somatrogon; FDA EU for SCONE device; Antengene ATG-010 for rrMM and rrDLBCL; SanBio STEMTRA Phase 2 Interim Results

Improving cancer immunotherapy; Senseonics’ Eversense delayed; FDA acknowledges Alkermes’ Resubmission; 3D breast ultrasound improves diagnosis

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche’s bispecific matches Eylea; Research Updates in Leukemia, solid tumors

Agios’ cancer pipeline auction; uniQure’s gene therapy on hold; Ultragenyx, Mereo Deal; aTyr Pharma Trial

Mitochondria destruction for Cancer Treatment; Atsena raises USD 55 Million financings; Novartis and Cadent Therapeutics collaboration; Neuron23’s strategy to tackle CNS disorders

FTA for Gannex’s ASC4; Disappointment for Incyte’s Ruxolitinib; Historic win for Pfizer, BioNTech’s COVID Vaccine; Alexion buyout; the debut of InnoSkel

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

More Views & Analysis

KaliVir, Astellas licensing deal; AbCellera’s IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

BASE10 Collaboration; Advaxis Public offerings; Takeda’s CABOMETYX Japan approval; TheraPharm Acquisition

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant’s vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic

Novartis’ COVID-19 deal; Shattered hopes for Remdesivir; Lilly’s R&D pact with Precision; Innovent’s Humira Biosimilar

Pfizer succeeds COVID-19 vaccine safety milestone; Sanofi snags speedy review for BTK drug; Autoimmune diseases research updates; Elevation Oncology secures $65 M

Albireo Pharma’s PFIC Therapy; Lupin’s Trichomoniasis Oral Drug; Moderna’s Weapon Against COVID; Gilead & Novo Nordisk’s Cocktail Therapy for NASH

FDA authorizes first diagnostic test for Covid-19 antibodies; EGenesis’s collaboration with Duke; Pancreatic Cancer research updates; Decibel scores $ 82 M

Subscribe to our Updates

Daily

Weekly

Monthly